Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) Research & Development (2020 - 2026)

GeneDx Holdings has reported Research & Development over the past 7 years, most recently at $19.8 million for Q1 2026.

  • Quarterly Research & Development rose 57.46% to $19.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $79.3 million through Mar 2026, up 69.59% year-over-year, with the annual reading at $72.0 million for FY2025, 57.53% up from the prior year.
  • Research & Development was $19.8 million for Q1 2026 at GeneDx Holdings, down from $24.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $27.2 million in Q2 2022 and troughed at $10.9 million in Q2 2024.
  • The 5-year median for Research & Development is $14.6 million (2023), against an average of $16.6 million.
  • The largest YoY upside for Research & Development was 127.31% in 2022 against a maximum downside of 59.88% in 2022.
  • A 5-year view of Research & Development shows it stood at $24.4 million in 2022, then tumbled by 49.73% to $12.2 million in 2023, then fell by 5.39% to $11.6 million in 2024, then surged by 111.78% to $24.5 million in 2025, then decreased by 19.3% to $19.8 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Research & Development are $19.8 million (Q1 2026), $24.5 million (Q4 2025), and $19.8 million (Q3 2025).